Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 184-190

  Bosset, Jean François ^a   Calais, Gilles ^b   Mineur, Laurent ^c   Maingon, Philippe ^d   Stojanovic Rundic, Suzana ^e   Bensadoun, René Jean ^f   Bardet, Etienne ^g   Beny, Alexander ^h   Ollier, Jean Claude ⁱ   Bolla, Michel ^j   Marchal, Dominique ^k   Van Laethem, Jean Luc ^l   Klein, Vincent ^m   Giralt, Jordi ⁿ   Clavère, Pierre ^o   Glanzmann, Christoph ^p   Cellier, Patrice ^q   Collette, Laurence ^r  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c INSTITUT SAINTE CATHERINE   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^f UNIVERSITÉ DE POITIERS   (France)

^g Centre de Nantes   (France)

^h RAMBAM MEDICAL CENTER   (Israel)

ⁱ Department of Surgery   (France)

^j HÔPITAL MICHALLON   (France)

^k Centre Hospitalier Universitaire de Charleroi   (Belgium)

^l ERASME HOSPITAL   (Belgium)

^m Clinique St Yves   (France)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^o LIMOGES UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q Institut de Cancérologie de l'Ouest Centre Paul Papin ^*  (France)

^r EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; FLUOROURACIL; HUMANS; INTENTION TO TREAT ANALYSIS; ISRAEL; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893020737     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70599-0     Document Type: Article

References (23)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
2. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
3. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy with rectal cancer. N Engl J Med 2006, 355:1114-1123.
4. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the EORTC Radiation Oncology Group. J Clin Oncol 2007, 25:4379-4386.
5. Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer 2004, 40:219-224.
6. Freedman LS, White SJ On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976, 32:691-694.
7. Kalbfleisch JD, Prentice RL The statistical analysis of failure time data 2002, John Wiley. second edition.
8. Fine JP, Gray RJ A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 1999, 94:496-509.
9. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012, 13:579-588.
10. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13:679-687.
11. Ngan SY, Burmeister B, Fisher RJ, et al. Randomised trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol 2012, 30:3827-3833.
12. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012, 3. CD004078.
13. Cionini L, Sainato A, De Paoli A, et al. Final results of randomised trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010, 96(suppl 1):S113.
14. Breugom AJ, van den Broek CBM, van Gijn W, et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TME-surgery: the PROCTOR/SCRIPT study. Eur J Cancer 2013, 49(suppl 3):S1.
15. Bujko K, Glynne-Jones R, Bujko M Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010, 21:1743-1750.
16. NCCN Clinical Practical Guidelines in Oncology. Version 4.2013 Rectal cancer, (accessed May 24, 2013). http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
17. Glimelius B, Oliveira J Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(suppl 4):54-56. ESMO Guidelines Working Group.
18. Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009, 92:148-163.
19. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
20. Neoadjuvant chemoradiotherapy and adjuvant chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in rectal cancer CAO-ARO-AIO-04 trial, (accessed May 22, 2013). http://www.kgu.de/uploads/media/Protocol_Synopsis_CAO-ARO-AIO-04.pdf.
21. A clinical trial comparing preoperative radiation therapy and capecitabine with or without oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum NSABP R-04 trial, (accessed May 22, 2013). http://www.nsabp.pitt.edu/R-04.asp.
22. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs.capecitabine alone in locally advanced rectal cancer (PETACC-6) EORTC 40054-22062 trial, (accessed May 22, 2013). http://cancer.gov/clinicaltrials/EORTC-40054.
23. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:241-248.